HomeCompareAICOF vs PFE

AICOF vs PFE: Dividend Comparison 2026

AICOF yields 200000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AICOF wins by $4.911780474428384e+29M in total portfolio value
10 years
AICOF
AICOF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full AICOF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AICOF vs PFE

📍 AICOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAICOFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AICOF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AICOF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AICOF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AICOF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AICOF + PFE for your $10,000?

AICOF: 50%PFE: 50%
100% PFE50/50100% AICOF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AICOF
No analyst data
Altman Z
-22.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AICOF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAICOFPFE
Forward yield200000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.911780474428384e+29M$49.6K
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00$26,258.71
Total dividends collected$4.911464459982279e+29M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AICOF vs PFE ($10,000, DRIP)

YearAICOF PortfolioAICOF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$20,010,700$20,000,000.00$9,153$693.39+$20.00MAICOF
2$37,424,589,019$37,403,177,570.09$8,593$849.25+$37424.58MAICOF
3$65,416,215,188,220$65,376,170,877,969.18$8,336$1,066.78+$65416215.18MAICOF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$8,437$1,384.80+$106868230495.00MAICOF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$9,013$1,875.40+$163172871735896.88MAICOF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$10,306$2,680.72+$232854599801468864.00MAICOF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$12,820$4,101.38+$310570858137017057280.00MAICOF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$17,673$6,826.70+$3.871481543016132e+23MAICOF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$27,543$12,591.86+$4.510617497632811e+26MAICOF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$49,560$26,258.71+$4.911780474428384e+29MAICOF

AICOF vs PFE: Complete Analysis 2026

AICOFStock

Generative AI Solutions Corp., an artificial intelligence company, focuses on development and commercialization of AI-powered tools and solutions for businesses and consumers across various industries in Canada. The company offers MAI Cloud, a cloud-based database; Remitz, which identifies and submits claims related to medical billing; and Classmate app, which utilizes natural language processing to find answers to educational questions. It also provides AI-powered products and services, including predictive analytics tools, chatbots, and machine learning platforms. In addition, the company is developing Tobacco Titan for the tobacco industry; and Global AI Newswire, which sends real-time press releases of publicly listed companies to users. It serves customers in education, healthcare, finance, and transportation industries. Generative AI Solutions Corp. is headquartered in Vancouver, Canada.

Full AICOF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AICOF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AICOF vs SCHDAICOF vs JEPIAICOF vs OAICOF vs KOAICOF vs MAINAICOF vs JNJAICOF vs MRKAICOF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.